These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 35396008)
1. [Research Advances of Immunotherapy for Follicular Lymphoma --Review]. Qiu LH; Zheng YX; Zheng ZR; Tian C Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):627-630. PubMed ID: 35396008 [TBL] [Abstract][Full Text] [Related]
2. Novel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma. Chin CK; Nastoupil LJ Hematol Oncol Clin North Am; 2020 Aug; 34(4):743-756. PubMed ID: 32586578 [TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory Agents in Follicular Lymphoma. Ysebaert L; Morschhauser F Hematol Oncol Clin North Am; 2020 Aug; 34(4):715-726. PubMed ID: 32586576 [TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-sparing treatment strategies for follicular lymphoma: current options and future directions. Ng SY; Abramson JS Curr Opin Hematol; 2016 Jul; 23(4):371-6. PubMed ID: 27213499 [TBL] [Abstract][Full Text] [Related]
6. An analysis of genetic targets for guiding clinical management of follicular lymphoma. Alonso-Alonso R; Rodriguez M; Morillo D; Cordoba R; Piris MA Expert Rev Hematol; 2020 Dec; 13(12):1361-1372. PubMed ID: 33176509 [No Abstract] [Full Text] [Related]
7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
10. Current therapeutic strategies and new treatment paradigms for follicular lymphoma. Kritharis A; Sharma J; Evens AM Cancer Treat Res; 2015; 165():197-226. PubMed ID: 25655611 [TBL] [Abstract][Full Text] [Related]
11. When to Use Targeted Therapy for the Treatment of Follicular Lymphoma. Nastoupil LJ Curr Hematol Malig Rep; 2021 Feb; 16(1):45-51. PubMed ID: 33797691 [TBL] [Abstract][Full Text] [Related]
12. [Development of mechanism-based targeted therapies for malignant lymphoma]. Rai S Rinsho Ketsueki; 2020; 61(9):1266-1274. PubMed ID: 33162525 [TBL] [Abstract][Full Text] [Related]
13. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma. Matsuki E; Younes A Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic targeting of microenvironment in follicular lymphoma. Nowakowski GS; Ansell SM Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):169-73. PubMed ID: 25696851 [TBL] [Abstract][Full Text] [Related]
16. Follicular lymphoma: Update on management and emerging therapies at the dawn of the new decade. Apostolidis J; Mokhtar N; Al Omari R; Darweesh M; Al Hashmi H Hematol Oncol; 2020 Aug; 38(3):213-222. PubMed ID: 31891210 [TBL] [Abstract][Full Text] [Related]
17. Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review. Hayslip J; Montero A Mol Cancer; 2006 Oct; 5():44. PubMed ID: 17026765 [TBL] [Abstract][Full Text] [Related]
18. New agents in follicular lymphoma. Cheson BD Best Pract Res Clin Haematol; 2011 Jun; 24(2):305-12. PubMed ID: 21658626 [TBL] [Abstract][Full Text] [Related]
19. Indolent lymphomas: pushing the pace with novel agents. Jacobson CA Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):279-286. PubMed ID: 31808854 [TBL] [Abstract][Full Text] [Related]